Should You Buy Defensive Stocks British American Tobacco plc, GlaxoSmithKline plc & Centrica PLC?

Will Defensive Stocks British American Tobacco plc (LON:BATS), GlaxoSmithKline plc (LON:GSK) & Centrica PLC (LON:CNA) Outperform In 2016?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

World markets remain unstable despite the recent rally in equities . Investors looking to park capital in stocks that should perform ok in a prolonged bear market should be researching defensive plays. Historically defensive stocks have been in the consumer, utilities and healthcare sectors. The three stocks below are perfect defensive stocks that should hold up well in a downturn. 

Tobacco king

British American Tobacco (LSE: BATS) has been an outstanding performer since the year 2000, the share price has increased by a whopping 629% and the company has returned billions to shareholders in the form of dividends. The company manages to maintain margins of 30-36% and generate over £4bn in net profit each year.

Shareholders will see a substantial amount of this profit returned in a dividend of 154p a share (3.9%) which is covered 1.6 times by cash. The company is relatively cheap too — currently shares are trading on a P/E ratio of just over 17. This is lower than London’s other large tobacco stock Imperial Brands (LSE: IMB). 

British American Tobacco is a great stock to own in times like these because of the defensive nature of tobacco companies and the huge profit the company has consistently delivered for years. 

Pharma giant

GlaxoSmithKline (LSE: GSK) is an extremely popular defensive stock in the US and UK. The company operates in the healthcare sector and is expected to have revenues of over £25bn this year. Glaxo pays out a punchy 6% dividend and the shares still only trade on a P/E of 15, which is firmly in the bottom half of  its peer group.

The strong defensive qualities can be seen when looking at a 10 year chart for the stock — impressively the stock rose in during the 2008/2009 global financial crisis. This would suggest that if the world economy enters another recession then Glaxo shares would be a great place to have invested. 

The company has developed an exciting range of new drugs and treatments to help fill the revenue gap left by old treatments coming off patents. Although revenue is declining the company is keeping profits relatively steady, and the stock is definitely one to own in a downturn.  

UK utility

Utility stocks such as Centrica (LSE: CNE) are not something I would usually look at. However, in the current economic climate the sector may well outperform others by the end of the year. The headline attraction to Centrica is the 5.3% dividend yield but there could be a good turnaround story here.

After two years of losses the company is forecast to swing into a profit for 2016 and 2017 which could cause the shares to re-rate. The forecast P/E ratio for 2016 is 12.5 which is a good deal lower than its listed peers and that is something that I would expect to change. Centric has defensive qualities like the other stocks mentioned here but there is also considerable scope for capital growth. 

Centrica is reporting this week so that may give us some confirmation of the companies change in fortunes and the outlook going forward. 

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 top FTSE 250 investment trusts to consider in April

The FTSE 250 is brimming with high-quality investment trusts. Our writer highlights two very different options, including a mid-cap newcomer.

Read more »

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
Investing Articles

After making a fortune on Tesla, this FTSE 250 trust has piled into a little-known S&P 500 stock

Baillie Gifford made huge profits from S&P 500 growth stocks like Nvidia. Lately, it's been snapping up a lesser-known tech…

Read more »

ISA coins
Investing Articles

How much do you need in a Stocks and Shares ISA to target a £1,200 a year passive income?

A FTSE 100 index fund comes with a 3% dividend yield. But can income investors find better opportunities for their…

Read more »

piggy bank, searching with binoculars
Value Shares

What’s going on with the Greggs share price now?

Dr James Fox takes a look at the Greggs share price which has suffered more than most over the past…

Read more »

Middle aged businesswoman using laptop while working from home
Dividend Shares

2 UK shares with over 20 years of consecutive dividend growth

Jon Smith points out a couple of UK shares with strong dividend credentials that lead him to dig deeper and…

Read more »

ISA Individual Savings Account
Investing Articles

1 penny stock I feel comfortable putting in a Stocks and Shares ISA

When picking assets for a Stocks and Shares ISA, penny stocks are usually low on the list. But I think…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

£20,000 invested in the FTSE 100 just 1 year ago would now be worth…

Historically speaking, we've just witnessed one of the single greatest 12-month stretches in the history of the FTSE 100 index.

Read more »

ISA coins
Investing Articles

Here’s how a £20k ISA could earn you £10k a month in passive income

£20k in a Stocks and Shares ISA waiting to be invested? Royston Wild explains how you could use this to…

Read more »